A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
for Non-small Cell Lung Cancer
Drug: Relatlimab
45 locations incl. Mobile
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT06561386·Phase 3·Recruiting